The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptorLivia Stanger, Michael Holinstat, Devin Gilmore et al.|Blood|2023Cited by 18
CS585 Demonstrates Favorable Selectivity and Sustained <i>In Vivo</i> Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor AgonistsLivia Stanger, Michael Holinstat, Sylviane Lambert et al.|Blood|2023Cited by 0